Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial

[1]  C. Cooper,et al.  The Institutional Review Board. , 2017, Journal of pediatric urology.

[2]  V. Apostolopoulos,et al.  Cellular Mucins: Targets for Immunotherapy. , 2017, Critical reviews in immunology.

[3]  R. Motzer,et al.  CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC) , 2015 .

[4]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[5]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[6]  B. Loveland,et al.  Update on Mucin-1 immunotherapy in cancer: a clinical perspective , 2015, Expert opinion on biological therapy.

[7]  V. Apostolopoulos,et al.  MUC1 (CD227): a multi-tasked molecule , 2015, Cellular and Molecular Life Sciences.

[8]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[9]  C. Gunderson,et al.  Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer. , 2015, Future oncology.

[10]  C. Toniatti,et al.  Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination. , 2015, Journal of medicinal chemistry.

[11]  B. Monk,et al.  Incorporation of pazopanib in maintenance therapy of ovarian cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Quinn,et al.  A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer , 2014, Journal of Immunotherapy for Cancer.

[13]  J. Berek,et al.  Study of autologous dendritic cell therapy targeting Mucin 1 as a treatment for the maintenance of ovarian cancer patients in remission , 2013, Journal of Immunotherapy for Cancer.

[14]  H. Maecker,et al.  Qualification of an intracellular cytokine staining (ICS) assay to evaluate mucin 1-specific T cell responses in ovarian cancer patients treated with CVAC immunotherapy , 2013 .

[15]  A. Al-Niaimi,et al.  Epithelial ovarian cancer. , 2012, Obstetrics and gynecology clinics of North America.

[16]  Jeffrey J H Low,et al.  Epithelial ovarian cancer , 2018, An Atlas of Gynecologic Oncology.

[17]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[18]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[19]  J. Taylor‐Papadimitriou,et al.  MUC1 immunotherapy. , 2010, Immunotherapy.

[20]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[21]  R. Barakat.  Principles and Practice of Gynecologic Oncology , 2009 .

[22]  D. Alberts,et al.  An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Perkins,et al.  Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. , 2007, Gynecologic oncology.

[24]  V. Apostolopoulos,et al.  Mannan-MUC1–Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma , 2006, Clinical Cancer Research.

[25]  E. Eisenhauer,et al.  Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer) , 2005 .

[26]  E. Eisenhauer,et al.  Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). , 2005, Journal of the National Cancer Institute.

[27]  P. Chu,et al.  Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. , 2004, American journal of clinical pathology.

[28]  E. Eisenhauer,et al.  Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). , 2005, Journal of the National Cancer Institute.

[29]  M. Parmar,et al.  Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. , 2000, Journal of the National Cancer Institute.

[30]  C. Perez,et al.  Principles and Practice of Gynecologic Oncology , 1992 .